Business Description
Amicus Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03152W1099
Share Class Description:
FOLD: Ordinary SharesCompare
Compare
Traded in other countries / regions
FOLD.USAAM6.Germany0HF9.UKFOLD.Mexico IPO Date
2007-05-31Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | 0.15 | |||||
| Debt-to-Equity | 4.05 | |||||
| Debt-to-EBITDA | -3.19 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.48 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.5 | |||||
| 3-Year EBITDA Growth Rate | 20.7 | |||||
| 3-Year EPS without NRI Growth Rate | 17.9 | |||||
| 3-Year FCF Growth Rate | 19.4 | |||||
| 3-Year Book Growth Rate | -38.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 19.44 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.26 | |||||
| 9-Day RSI | 37.74 | |||||
| 14-Day RSI | 39.9 | |||||
| 6-1 Month Momentum % | 14.96 | |||||
| 12-1 Month Momentum % | 25.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.72 | |||||
| Quick Ratio | 2.4 | |||||
| Cash Ratio | 1.67 | |||||
| Days Inventory | 256.04 | |||||
| Days Sales Outstanding | 63.09 | |||||
| Days Payable | 167.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.2 | |||||
| Shareholder Yield % | -2.89 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.91 | |||||
| Operating Margin % | -36.74 | |||||
| Net Margin % | -52.86 | |||||
| ROE % | -144.06 | |||||
| ROA % | -24.94 | |||||
| ROIC % | -39.23 | |||||
| ROC (Joel Greenblatt) % | -229.2 | |||||
| ROCE % | -25.1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 53.65 | |||||
| PS Ratio | 10.06 | |||||
| PB Ratio | 31.18 | |||||
| EV-to-EBIT | -24.25 | |||||
| EV-to-Forward-EBIT | 43.98 | |||||
| EV-to-EBITDA | -25.29 | |||||
| EV-to-Forward-EBITDA | 41.79 | |||||
| EV-to-Revenue | 10.24 | |||||
| EV-to-Forward-Revenue | 6.9 | |||||
| EV-to-FCF | -26.95 | |||||
| Earnings Yield (Greenblatt) % | -4.12 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FOLD
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amicus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 350.56 | ||
| EPS (TTM) ($) | -0.64 | ||
| Beta | 0.55 | ||
| Volatility % | 33.73 | ||
| 14-Day RSI | 39.9 | ||
| 14-Day ATR ($) | 0.521101 | ||
| 20-Day SMA ($) | 12.6675 | ||
| 12-1 Month Momentum % | 25.58 | ||
| 52-Week Range ($) | 9.1 - 14.1 | ||
| Shares Outstanding (Mil) | 287.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amicus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amicus Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amicus Therapeutics Inc Frequently Asked Questions
What is Amicus Therapeutics Inc(FOLD)'s stock price today?
The current price of FOLD is $12.16. The 52 week high of FOLD is $14.10 and 52 week low is $9.10.
When is next earnings date of Amicus Therapeutics Inc(FOLD)?
The next earnings date of Amicus Therapeutics Inc(FOLD) is 2023-11-07 Est..
Does Amicus Therapeutics Inc(FOLD) pay dividends? If so, how much?
Amicus Therapeutics Inc(FOLD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers